Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Increase in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 63,309 shares, an increase of 294.1% from the November 30th total of 16,064 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 287,693 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 287,693 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Analysts Set New Price Targets

ALPMY has been the subject of a number of research analyst reports. Sanford C. Bernstein downgraded shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 2nd. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Astellas Pharma has an average rating of “Hold”.

Astellas Pharma Price Performance

OTCMKTS ALPMY opened at $13.40 on Thursday. The company’s fifty day simple moving average is $12.08 and its 200-day simple moving average is $11.06. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. Astellas Pharma has a 52 week low of $8.37 and a 52 week high of $13.92.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.21%. The firm had revenue of $3.45 billion for the quarter, compared to analyst estimates of $3.14 billion. As a group, research analysts expect that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).